When people talk about “FDA reports” for GLP-1 drugs like Ozempic, Wegovy, Mounjaro, Zepbound, Rybelsus, Trulicity, Saxenda, and Victoza, they’re usually referring to post-marketing safety data — especially the FDA’s adverse event reporting system. These reports don’t automatically prove a drug caused an injury, but they can reveal patterns that matter for patient safety, medical research, and litigation.
The FDA has promulgated numerous critical reports related to GLP-1 medications. Most GLP-1 reports focus on ameliorating shortages of drugs, coming down hard on non-approved compounded knock off GLP-1 versions, and weighing in on safety issues such as suicidal ideation and errors in dosing.
Recent updates that are regulatory & medication approvals: New GLP-1 medication greenlighted. On April 1, 2026, the FDA approved Foundayo (orforglipron). Foundayo is an oral GLP-1 pill manufactured by Eli Lilly for people 18+ who are fat.
Shortage resolutions: The FDA formally stated that the GLP shortages in the U.S. for both tirzepatide (Zepbound/Mounjaro) and semaglutide (Ozempic/Wegovy ) have ended since late 2024 and the beginning of 2025.
GL1P-1 Compounding crackdown: With the shortages under control, the FDA has layed down the law- that compounding pharmacies must move away from production that is routine of this medication. The FDA has commenced an epic crackdown on marketing “unapproved” GLP-1s that are compounded. The FDA promulgated letters of warning to 30 telehealth corporations in March 2026 for misleading marketing assertions.
Reports that are safety related & FDA findings: In March 2026, the FDA demanded that Eli Lilly and Novo Nordisk remove suicidal ideation and suicidal behavior from the warning label of Saxenda, Wegovy and Zepbound. An all-inclusive meta-analysis of over 99,000 people determined that patients had no greater risk of suicidal thoughts as a result of GLP-1 drugs.
Dosing errors: The FDA has promulgated numerous warnings related to adverse events linked to dosing errors, most notably concerning compounded prescriptions when people utilize syringes to make up their own dose instead of utilizing the pre-filled pens (jabs).
Enforcement actions: The FDA instituted a “green list” to stop illegal imported ingredients of GLP-1 from getting into America’s supply chain. The FDA specifically targeted substances such as salt forms (semaglutide sodium) which are not part of FDA approved GLP-1s.
Novo Nordisk warning: In March 2026, the FDA promulgated a letter of warning to Novo Nordisk for not reporting numerous adverse events, which includes three victim fatalities, within mandated timeframes
This page explains what FDA adverse event reports are, what they can (and cannot) show, and how they’re commonly used in GLP-1 lawsuit investigations
What “FDA Reports” Usually Means
In most GLP-1 safety discussions, “FDA reports” refers to:
- FAERS (FDA Adverse Event Reporting System) submissions
- safety communications / labeling updates (when they occur)
- post-marketing surveillance signals reviewed by regulators
FAERS is the most commonly referenced dataset in lawsuits because it contains large volumes of real-world incident reports.
What Is FAERS?
FAERS is a database where adverse events are reported by:
- patients and caregivers
- doctors and hospitals
- drug manufacturers (who are required to submit certain reports)
FAERS reports may include:
- drug name
- injury or diagnosis
- outcomes (hospitalization, disability, death, etc.)
- timing and narrative details (varies widely)
What FAERS Can Show
FAERS can help identify:
- clusters of similar injuries reported for a medication
- emerging safety patterns not obvious in early trials
- whether injuries are being reported across many unrelated reporters
- whether certain outcomes (hospitalization, surgery, disability) appear repeatedly
In GLP-1 litigation context, this is often framed as:
“Were serious injury patterns visible in real-world reporting?”
What FAERS Cannot Prove (Important)
FAERS has major limitations:
- a report does not prove causation
- reports can be incomplete, duplicated, or biased
- underreporting is common
- many cases involve confounders (other meds, other conditions)
That’s why lawsuits typically rely on FAERS + medical records + expert analysis, not FAERS alone.
Adverse Events Commonly Discussed in GLP-1 Litigation
FAERS-linked discussions in GLP-1 claims frequently involve:
- gastroparesis / stomach paralysis
- intestinal obstruction / severe motility disorder
- pancreatitis
- kidney injury / kidney failure (often dehydration-driven)
- gallbladder disease / gallbladder removal
- severe vomiting and dehydration requiring ER care
Related pages:
- Gastroparesis claims
- Intestinal obstruction
- Pancreatitis claims
- Kidney failure claims
- Gallbladder removal claims
How FDA Reporting Data Can Relate to Lawsuits
In product liability cases, adverse event reporting patterns may be used to support arguments such as:
- serious injuries were being reported consistently
- warnings may not have reflected real-world severity
- injury patterns may have been foreseeable as prescriptions expanded
- GI “slowing” risks may be more severe in some patients than commonly understood
This is part of broader “failure-to-warn” style analysis (which varies by jurisdiction and claim type).
How Lawyers and Experts Use FDA Reporting Data
In practice, legal teams may use FAERS data to:
- identify recurring injury categories for investigation
- prioritize case types (e.g., gastroparesis + hospitalization)
- compare injury narratives to medical mechanisms
- support expert opinions (alongside scientific literature and medical records)
Your individual case still depends most heavily on your medical documentation.
➡️ Records guide: Medical Records
Do You Need an FDA Report to Have a Case?
No. Many strong claims exist without an FDA report filed.
A legal claim typically focuses on:
- diagnosis and severity
- medical care (ER/hospitalization/surgery)
- timeline and persistence
- objective testing (labs, scans, motility studies)
➡️ What lawyers look for: What Lawyers Look For
Should You File an FDA Report?
Some people choose to file a report to document what happened. Reasons include:
- adding to the safety record
- helping regulators identify trends
- contributing to broader awareness
But again: filing an FDA report is not required to pursue legal review.
Start a Claim Review (Even If You’re Still Researching)
If you had hospitalization, surgery, organ injury, or long-term impairment after GLP-1 use, you can begin with minimal information.
➡️ Start here: File a Claim
➡️ Eligibility criteria: Criteria
Related
FDA adverse event reporting (FAERS) is a major source of post-marketing safety information for GLP-1 drugs. While it cannot prove causation on its own, repeated patterns across many reports can help identify potential safety signals and inform litigation investigations. For individual claims, medical records and objective diagnosis remain the most important evidence.
➡️ Start your review: File a Claim